Robert Rintoul is Professor of Thoracic Oncology in the Department of Oncology, University of Cambridge and Honorary Consultant Respiratory Physician, Royal Papworth Hospital. He trained in respiratory medicine in London and Edinburgh receiving his doctorate from the University of Edinburgh for work investigating mechanisms underlying resistance to chemotherapy in small cell lung cancer. He was appointed consultant in respiratory medicine specialising in thoracic oncology at Royal Papworth Hospital in 2005 before moving into the University of Cambridge in 2017. Professor Rintoul is lead clinician for cancer at Royal Papworth Hospital and Director of the Papworth Trials Unit Collaboration. He is co-lead of the CRUK Cambridge Centre Thoracic Cancer Programme and facilitates thoracic oncology research across Cambridge.

Professor Rintoul’s research is focused around clinical trials, translational research and tissue banking in malignant mesothelioma and the early detection of lung cancer. He is Chief Investigator for several clinical translational studies examining biomarkers in lung cancer. In 2014 he founded Mesobank, the UK national bioresource for malignant mesothelioma (www.mesobank.com). His work is funded by the Cambridge Biomedical Research Centre, Cancer Research UK, National Institute for Health Research and Asthma and Lung UK.
He is a member of the Roy Castle Lung Cancer Clinical Expert Group and is currently Chair of the Clinical Advisory Group of the UK Lung Cancer Coalition.